Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Vietnam Blames Deputy Minister, DAV For Broader Vaccine Approval

This article was originally published in PharmAsia News

Executive Summary

Vietnam authorities blame a deputy minister of health and the nation's drug agency for allowing wider use of a pair of cervical cancer vaccines than generally permitted. An inspector for the Ministry of Health was ordered to look into the issue after Merck Sharp and Dohme, and GlaxoSmithKline were accused of improper lobbying to get the broader-use recommendation. The inspector said the deputy minister and the Drug Administration of Vietnam were responsible for approving Merck's Gardasil and GSK's Cervarix for women as old as 55 instead of the normal age span of 10 to 25. The deputy and DAV leaders ordered two medical councils involved to reconsider the age of users, the inspector said. (Click here for more

You may also be interested in...



Global Pharma Guidance Tracker – June 2020

Stay up to date on regulatory guidelines from around the world with the Pink Sheet's Guidance Tracker. The complete Global Pharma Guidance Tracker, with sortable and searchable listings going back to 2014, is available online.

Mylan And Upjohn Unveil Viatris Logo And Branding

Drawing on the company’s Latin name, Viatris – the proposed combination of Mylan and Upjohn – has unveiled a logo and branding “capturing the company’s commitment to access, leadership and partnership.”

Hansa Raises $121m To Fund Idefirix Launch

Having recently signed a gene therapy collaboration with Sarepta and received a positive opinion from the CHMP for its kidney transplant therapy, Sweden's Hansa has now raised a substantial sum in a "multiple times oversubscribed" placing.

UsernamePublicRestriction

Register

LL025498

Ask The Analyst

Please Note: Click here for more information on the Ask the Analyst service.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel